Additionally, tirzepatide, the first dual GIP /GLP-1 receptor co-agonist approved for treating T2DM in several regions, has demonstrated unprecedented reductions in both HbA1c and body weight [253]. The gene discussed is GIP; the disease is type 2 diabetes mellitus.